CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Sloy Dahl & Holst LLC

Sloy Dahl & Holst LLC increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,353 shares of the company’s stock after purchasing an additional 723 shares during the quarter. Sloy Dahl & Holst LLC’s holdings in CRISPR Therapeutics were worth $460,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Blue Trust Inc. acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $32,000. Bourgeon Capital Management LLC grew its position in CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares in the last quarter. CWM LLC grew its position in CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares in the last quarter. TFC Financial Management Inc. grew its position in CRISPR Therapeutics by 3,400.0% in the fourth quarter. TFC Financial Management Inc. now owns 700 shares of the company’s stock valued at $44,000 after acquiring an additional 680 shares in the last quarter. Finally, Tradewinds Capital Management LLC grew its position in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after acquiring an additional 600 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CRSP. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Wolfe Research began coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Wells Fargo & Company increased their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Morgan Stanley increased their price objective on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Finally, Mizuho raised their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $74.93.

CRISPR Therapeutics Stock Performance

CRSP traded down $1.03 during trading hours on Wednesday, hitting $56.93. 234,928 shares of the stock were exchanged, compared to its average volume of 1,830,881. The stock has a 50-day simple moving average of $73.89 and a 200-day simple moving average of $63.30. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The firm had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. During the same quarter last year, the business earned ($1.41) earnings per share. The business’s revenue for the quarter was up 3253.3% compared to the same quarter last year. Equities research analysts forecast that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the sale, the chief executive officer now directly owns 187,377 shares in the company, valued at $15,057,615.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold 114,410 shares of company stock worth $7,984,677 over the last ninety days. 4.10% of the stock is owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.